Cartesian announces positive updated Phase 2b data for Descartes-08 in MG; Phase 3 AURORA on track for H1 2025

Cartesian Therapeutics, Inc.

Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.
Responses durable through Month 12: 80% (4/5) maintained clinically meaningful improvement.
No CRS or ICANS reported; safety supports outpatient administration without lymphodepleting chemo.
Phase 3 AURORA trial (n≈100) to begin H1 2025; primary endpoint: ≥3-point MG-ADL improvement vs placebo at Month 4.
Retreated Phase 2a patients showed rapid responses again; no new safety signals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.